Market Overview - The medical device sector rose by 1.16% on August 12, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3665.92, up 0.5%, while the Shenzhen Component Index closed at 11351.63, up 0.53% [1] Top Gainers in Medical Device Sector - Mai Lande (688273) closed at 52.83, up 18.06%, with a trading volume of 150,500 shares and a transaction value of 771 million [1] - Sanxin Medical (300453) closed at 10.75, up 14.24%, with a trading volume of 810,000 shares [1] - Xiangyu Medical (688626) closed at 64.40, up 11.02%, with a trading volume of 102,800 shares [1] - Maipu Medical (301033) closed at 88.80, up 10.38%, with a trading volume of 24,000 shares [1] - Ruimaite (301367) closed at 97.77, up 6.63%, with a trading volume of 33,200 shares [1] Decliners in Medical Device Sector - Kehua Bio (002022) closed at 7.58, down 3.44%, with a trading volume of 417,400 shares [2] - Yirui Bio (300942) closed at 12.91, down 2.93%, with a trading volume of 104,400 shares [2] - Rendu Bio (688193) closed at 51.64, down 2.68%, with a trading volume of 8,204 shares [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 730 million from institutional investors, while retail investors saw a net inflow of 112 million [2] - The top stocks with significant net inflows from retail investors include Yirui Medical and Mai Lande, while major outflows were observed in stocks like Aiyu Technology and Meihua Medical [3]

Core Viewpoint - Yirui Technology's stock closed at 93.5 yuan, up 5.79%, with a rolling PE ratio of 39.92, marking a new low in 39 days, and a total market value of 18.72 billion yuan [1] Company Summary - Yirui Technology specializes in the research, production, sales, and service of digital X-ray detectors, high-voltage generators, combination ray sources, and tubes [1] - The main products include the universal series, dental series, mammography series, radiotherapy series, industrial series, high-voltage generators, and combination ray sources [1] - As of the first quarter of 2025, the company reported operating revenue of 482 million yuan, a year-on-year decrease of 1.92%, and a net profit of 143 million yuan, a year-on-year increase of 2.74%, with a gross profit margin of 48.92% [1] Industry Summary - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Yirui Technology at 77th in the industry ranking [1] - As of the first quarter of 2025, 51 institutions hold shares in Yirui Technology, with a total of 17.0041 million shares valued at 1.49 billion yuan [1] - The industry average market value is 11.897 billion yuan, while the median market value is 5.767 billion yuan [2]

Core Viewpoint - The company, Yirui Technology, announced that it will not adjust the conversion price of its convertible bonds downward, even if the conditions for downward adjustment are triggered again within the next six months [1] Summary by Sections - **Company Decision**: The board of directors of Yirui Technology decided not to propose a downward adjustment to the conversion price of the "Yirui Convertible Bonds" [1] - **Time Frame**: This decision is effective until February 7, 2026, and applies to any future triggers of the downward adjustment clause within the next six months from the announcement date [1]

Core Viewpoint - The company has decided not to adjust the conversion price of its convertible bonds, despite triggering conditions for a downward adjustment due to stock price performance [1][7]. Summary by Sections Convertible Bond Basic Information - The company issued a total of 14,350,100 convertible bonds at a face value of 100 RMB each, raising a total of 1,435.01 million RMB [1]. - The bonds have been trading on the Shanghai Stock Exchange since November 18, 2022, under the name "Yirui Convertible Bonds" and code "118025" [1]. Conversion Price Adjustments - The conversion price was adjusted from 499.89 RMB/share to 499.26 RMB/share in 2023 due to the company's stock incentive plan [2]. - Following the 2022 annual profit distribution, the conversion price was further adjusted to 354.54 RMB/share starting April 24, 2023 [2]. - A downward adjustment to 230.00 RMB/share is set to take effect on November 28, 2023, due to stock price performance [3]. - Subsequent adjustments will occur based on further corporate actions, including profit distributions and stock incentive plans, with the conversion price reaching 115.50 RMB/share by June 19, 2025 [4][5]. Downward Adjustment Conditions - The company triggered the condition for a downward adjustment when its stock price was below 85% of the conversion price for at least 15 trading days within a 30-day period [6][7]. - The board of directors decided not to propose a downward adjustment for the conversion price, even if the conditions are met again within the next six months [7].

| 证券代码：688301 | 证券简称：奕瑞科技 公告编号：2025-051 | | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | 奕瑞电子科技集团股份有限公司 关于不向下修正"奕瑞转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会关于可转换公司债券发行的有关规定和《上海 奕瑞光电子科技股份有限公司向不特定对象发行可转换公司债券募集说明书》 （以下简称"《募集说明书》"）的约定，公司发行的"奕瑞转债"自 2023 年 4 月 28 日起可转换为本公司股份，初始转股价格为 499.89 元/股。 1 因公司 2021 年限制性股票激励计划首次授予部分第一个归属期归属登记， "奕瑞转债"转股价格从 499.89 元/股调整为 499.26 元/股。具体内容详见公司于 2023 年 3 月 11 日在上海证券交易所网站（www.sse.com.cn）披露的《上海奕瑞 光电子科技股份有限公司关于"奕瑞转债"转股价格调整的公告》（公告编号： 2023- ...

Core Insights - The Shanghai Stock Exchange Science and Technology Innovation Board Medical Index (Sci-Tech Medical Index) reported a value of 807.76 points, showing a low opening and a high closing on August 4 [1] - The Sci-Tech Medical Index has increased by 8.56% over the past month, 13.65% over the past three months, and 11.39% year-to-date [2] Index Composition - The Sci-Tech Medical Index includes no more than 30 listed companies in the medical field from the Sci-Tech Innovation Board, reflecting the overall performance of these securities [2] - The index is based on a starting point of 1000.0 points as of December 30, 2022 [2] - The top ten weighted companies in the index are: - Huatai Medical (9.47%) - United Imaging (9.08%) - Hotgen Biotech (8.33%) - Aibo Medical (6.07%) - Yirui Technology (6.05%) - Nanwei Medical (5.62%) - Xinmai Medical (4.81%) - Shengxiang Biotech (4.6%) - Haier Biomedical (3.76%) - Tianzhihang (3.29%) [2] Market and Sector Breakdown - The Sci-Tech Medical Index is fully composed of companies listed on the Shanghai Stock Exchange [3] - The sector distribution of the index's holdings is as follows: - Medical consumables: 42.88% - Medical devices: 28.80% - In-vitro diagnostics: 28.32% [3] - The index samples are adjusted quarterly, with adjustments occurring in the second Friday of March, June, September, and December [3]

Group 1 - The company issued convertible bonds totaling RMB 1,435.01 million, with a net amount of RMB 1,421.31 million after deducting issuance costs [1][2] - The convertible bonds were listed on the Shanghai Stock Exchange on November 18, 2022, with an initial conversion price of RMB 499.89 per share, currently adjusted to RMB 115.50 per share [2] - The conversion price can be adjusted downwards if the company's stock price closes below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [3] Group 2 - The adjustment proposal for the conversion price must be approved by more than two-thirds of the voting rights at the shareholders' meeting, excluding bondholders from voting [3] - If the conversion price is adjusted, the new price will not be lower than the average trading price of the company's stock over the 20 trading days prior to the shareholders' meeting [3] - There is a potential trigger for the conversion price adjustment, as the company's stock has closed below 85% of the current conversion price for ten trading days from July 18 to July 31, 2025 [4]

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-050 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于"奕瑞转债"预计满足转股价格修正条件的 提示性公告 二、可转债转股价格修正条款与可能触发情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、可转债发行上市概况 经中国证券监督管理委员会《关于同意上海奕瑞光电子科技股份有限公司向 不特定对象发行可转债注册的批复》（证监许可[2022]2167 号）同意注册申请， 奕瑞电子科技集团股份有限公司（以下简称"公司"）向不特定对象共计发行 14,350,100 张可转换公司债券，每张面值为人民币 100 元，按面值发行。本次发 行可转债募集资金总额为人民币 143,501.00 万元；扣除发行费用（不含增值税） 人民币 1,369.65 万元后，募集资金净额为人民币 142,131.35 万元，上述资金已全 部到位，经立信会计师事务所（特殊普通合伙）审验并于 ...

Core Viewpoint - The company Yirui Technology, known as the "first stock of digital X-ray detectors" on the Sci-Tech Innovation Board, is facing dual challenges from capital withdrawal and industry changes [1][2]. Group 1: Capital Movements - Early investors Sequoia Capital are planning to reduce their holdings by up to 2%, potentially cashing out approximately 350 million yuan at the current closing price, marking their sixth round of reductions [1][2]. - Sequoia Capital has cumulatively cashed out nearly 1.86 billion yuan over six rounds of reductions since 2021, with their current holding dropping to a historical low of 6.66% if the latest reduction is fully executed [2]. Group 2: Financial Performance - Yirui Technology has experienced a decline in profits for three consecutive years, with projected revenue of 1.831 billion yuan in 2024 (down 1.74% year-on-year) and a non-net profit of 439 million yuan (down 25.84% year-on-year) [3]. - In Q1 2025, the company reported revenue of 482 million yuan (down 1.92% year-on-year) and a non-net profit of 141 million yuan (down 9.19% year-on-year) [3]. - Shareholders are increasingly selling off their stakes, with a recent transaction involving a major shareholder selling shares at a 14% discount to market price, reflecting cautious expectations for short-term stock performance [3]. Group 3: Strategic Moves - In response to operational challenges, Yirui Technology is investing over 3 billion yuan in two major expansion projects, including an 1.8 billion yuan investment in a micro-display backplane project and an 1.174 billion yuan X-ray vacuum device project [4]. - The expansion projects represent 37% of the company's total assets for 2024 and are closely linked to the chairman's other company, Shiya Technology, which is preparing for an IPO despite not yet being profitable [4]. Group 4: Market Outlook - There are signs of potential recovery in the medical equipment procurement market, with a reported 41% year-on-year increase in procurement scale for the first half of 2025, particularly in CT and DR equipment, which are core applications for Yirui's detectors [5]. - However, Yirui Technology faces significant competition in the silicon-based OLED market from global giants like Sony, which dominate a market worth over 500 million USD, posing challenges in technology accumulation and cost control [6].

Core Viewpoint - The strategic cooperation between Yisray Technology and Brazil's VMI Group marks a significant step in enhancing bilateral trade and investment opportunities between China and Brazil, particularly in the medical and industrial sectors [1]. Group 1: Strategic Cooperation - Yisray Technology signed a strategic cooperation agreement with Brazil's VMI Group to deepen collaboration in the Brazilian market and explore opportunities in Latin America [1]. - VMI Group is a leading local manufacturer of X-ray imaging equipment in Brazil with 35 years of industry experience and a mature localized service network [1]. - This partnership aligns with China's Belt and Road Initiative and Brazil's Development Plan, showcasing a strong synergy between the two countries' economic strategies [1]. Group 2: Global Expansion and Production Capacity - As of 2024, Yisray Technology's products are sold in over 80 countries and regions, supported by nine technical service centers globally [2]. - The company has established a comprehensive customer service system and has set up overseas sales or service platforms in various countries, including the USA, Germany, and Brazil [2]. - Yisray Technology is expanding its production capacity with investments in its Hefei and Taicang production bases, aiming to enhance its global manufacturing footprint [2]. Group 3: Brand Development and Market Penetration - Yisray Technology is focused on enhancing its international brand influence while exploring new customer segments in various fields such as dental, industrial, and veterinary [3]. - The company actively participates in major global industry exhibitions to strengthen its market presence and customer engagement [3]. - The collaboration with VMI Group is expected to accelerate the penetration of X-ray technology in medical and industrial sectors, benefiting a wider audience [3].